Bright Minds Biosciences Announces Resignation of Board Member
January 09 2023 - 4:05PM
Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”)
(Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on
developing novel drugs for the targeted treatment of
neuropsychiatric disorders, epilepsy, and pain, today announced
that Dr. Doug Williamson has resigned from its Board of Directors.
Dr. Williamson has accepted a new full-time role that precludes his
participation on the Bright Minds Board.
“In his short tenure on the Board, Doug’s
scientific, clinical, and medical experience has proven invaluable
in supporting our efforts to develop the next generation of safe
and efficacious drugs for challenging brain disorders such as
resistant epilepsy, treatment resistant depression, PTSD, and pain.
We wish him well in his new endeavors,” stated Ian McDonald, CEO
and Co-founder of Bright Minds Biosciences.
“It has been an honor to serve on the Bright
Minds Board. While I am stepping down from this role, I look
forward to following the Company’s future progress as it works to
create novel therapeutics to improve patient lives,” said Dr. Doug
Williamson.
About Bright Minds
Bright Minds is focused on developing novel
transformative treatments for neuropsychiatric disorders, epilepsy,
and pain. Bright Minds has a portfolio of next-generation serotonin
agonists designed to target neurocircuit abnormalities that are
responsible for difficult to treat disorders such as resistant
epilepsy, treatment resistant depression, PTSD, and pain. The
Company leverages its world-class scientific and drug development
expertise to bring forward the next generation of safe and
efficacious drugs. Bright Minds’ drugs have been designed to
potentially retain the powerful therapeutic aspects of psychedelic
and other serotonergic compounds, while minimizing the side
effects, thereby creating superior drugs to first-generation
compounds, such as psilocybin.
Investor Contact:Lisa WilsonE:
lwilson@insitecony.comT: 917-543-9932
Ian McDonaldCEO and DirectorE: ian@brightmindsbio.comT: 647 407
2515
Bright Minds Biosciences (NASDAQ:DRUG)
Historical Stock Chart
From Apr 2024 to May 2024
Bright Minds Biosciences (NASDAQ:DRUG)
Historical Stock Chart
From May 2023 to May 2024